Cannabis Stock Bubble: Tilray's $300 Spike

Key Takeaways

• Tilray spiked to an intraday $300 on September 19, 2018, then collapsed.
• Canada legalized recreational cannabis on October 17, 2018, the bubble's anchor event.
• Constellation Brands invested $4 billion USD in Canopy Growth in 2018.
• Oversupply, slow retail rollout, and a vaping scare crushed the sector in 2019.

Background

For most of the 2010s, cannabis was a tiny, mostly private market with no clear path to mainstream finance. That changed when Canada moved to legalize recreational use nationally. The Cannabis Act, known as Bill C-45, received Royal Assent on June 21, 2018, and an Order in Council fixed October 17, 2018 as the day the law came into force, according to the Canada Gazette. Canada became the second country in the world after Uruguay, and the first in the G7, to legalize recreational cannabis at the national level.

A national, regulated market was a genuine first. It gave investors a story they could underwrite: legal demand, branded products, and licensed producers who had spent years building greenhouses ahead of the change. The Government of Canada framed the goal as keeping cannabis away from youth and profits away from criminals, while creating a strictly regulated legal supply.

The companies positioned to serve that market were a small group of Canadian licensed producers. Canopy Growth (TSX: WEED, NYSE: CGC), Aurora Cannabis, Tilray, and Cronos became the names retail investors learned. Most had little or no profit. Their appeal rested on the size of the market they might one day capture, not on current earnings, and that gap between promise and proof is the raw material of every mania.

What turned a sector story into a frenzy was the way US investors could finally buy in. Until mid-2018, the easiest way to own these names was on Canadian exchanges. When the first pure-play grower listed directly on a major US exchange, American speculative money found a fast lane into a theme it had only read about.

What Happened

The acute phase ran from the summer of 2018 into the legalization date, then reversed hard through 2019.

• June 21, 2018: The Cannabis Act receives Royal Assent in Canada.
• July 19, 2018: Tilray completes its IPO on the Nasdaq, the first cannabis IPO on a major US exchange.
• August 15, 2018: Constellation Brands announces a $5 billion CAD ($4 billion USD) investment in Canopy Growth.
• September 19, 2018: Tilray spikes to an intraday $300, is halted five times, and closes at $214.
• October 17, 2018: Recreational cannabis becomes legal across Canada.
• November 1, 2018: The Constellation-Canopy investment closes.
• Through 2019: The sector slides as oversupply, slow retail rollout, and a US vaping scare hit.

Tilray's listing lit the fuse. The company sold 10.35 million shares at an initial price to the public of $17.00 and received net proceeds of $163.6 million (C$216.9 million) after underwriting fees, per its SEC filing. The final IPO prospectuses were filed with the SEC on July 19, 2018. Because only a small slice of the company was floated, the freely tradable supply was thin, which set up an unusually violent move.

That move arrived on September 19, 2018. Tilray opened around $211, ran to a record intraday $300, and triggered repeated volatility halts. Nasdaq halted the stock five times that day, and it still closed at $214, up about 38 percent, after earlier erasing a climb of roughly 90 percent, according to CBC News and CNBC. At its intraday peak the company was briefly worth more than $26 billion, larger than several established firms, even though it had minimal revenue. Reporting tied the surge to news that Tilray had won US Drug Enforcement Administration approval to export a cannabis-derived drug for a clinical trial, layered on top of a thin float and heavy short interest.

The other defining event was a vote of confidence from outside the sector. On August 15, 2018, Constellation Brands, the drinks company behind Corona and Modelo in the US, announced it would invest $5 billion CAD ($4 billion USD) in Canopy Growth. The deal closed on November 1, 2018, lifting Constellation's stake in Canopy to roughly 37 percent, per Constellation's SEC filing. A blue-chip corporate buyer paying billions made the whole theme look validated, and prices across the group climbed into the legalization date.

Then legalization came and the trade unwound. Selling pressure that had begun in late 2018 turned into a grinding sector-wide decline through 2019, and the high-flyers led the way down.

Why It Happened

The cannabis stock bubble grew from a real catalyst that markets extrapolated far past the evidence. Several forces stacked on top of each other.

The first was a genuine, datable policy change. Unlike a vague theme, national legalization had a fixed start date, which gave promoters and buyers a countdown to rally around. A concrete event made the optimism feel grounded, even though the size and profitability of the legal market were still unknown.

The second was a supply-and-demand mismatch in the shares themselves. Tilray floated only a small number of shares, so its public float was tiny relative to the buying interest. When a lot of money chases a small number of available shares, prices can gap violently higher, and short sellers betting against the rise can be forced to buy back at any price. The five trading halts on September 19 are the fingerprint of that kind of forced, momentum-driven move rather than a calm repricing of the business.

The third was the validation effect of a marquee strategic investor. Constellation's $4 billion USD commitment to Canopy gave the entire sector an anchor of credibility. Investors reasoned that if a large, profitable consumer-goods company would pay that much, the future market must be enormous. That logic ignored a key detail: a strategic buyer is making a decade-long bet on optionality, not endorsing today's stock prices.

The fourth was the absence of an earnings anchor. Most of these companies lost money and traded on projected future market share, not cash flow. With no profits to value against, prices were set by sentiment and narrative, which can run far in either direction. When the only support under a price is the belief that someone will pay more tomorrow, the support is fragile.

The fifth was a gap between legalization on paper and a working market on the ground. Producers raced to build growing capacity for an expected demand surge, but provinces, especially Ontario, were slow to license and open retail stores. The result was too much product and too few legal places to sell it, which pushed wholesale prices down and undercut the revenue forecasts that the valuations depended on.

By the Numbers

• Tilray IPO: 10.35 million shares sold at $17.00, net proceeds of $163.6 million (C$216.9 million); prospectuses filed July 19, 2018. (Tilray SEC 8-K)
• Tilray September 19, 2018: opened near $211, hit an intraday record of $300, halted five times, closed at $214 (up about 38 percent). (CBC News; CNBC)
• Tilray peak market value: briefly more than $26 billion at the intraday high. (The Motley Fool)
• Constellation-Canopy deal: $5 billion CAD ($4 billion USD), announced August 15, 2018, closed November 1, 2018, lifting Constellation's stake to about 37 percent. (Constellation Brands SEC 8-K)
• Legalization date: October 17, 2018, fixed by Order in Council; Royal Assent June 21, 2018. (Canada Gazette; Government of Canada)
• Tilray 2019 decline: fell to $19.93 at the close on November 15, 2019, down more than 70 percent year to date. (CMC Markets / Opto)
• Sector ETF: the MJ marijuana ETF reached a 52-week high around $44.29 on October 16, 2018, the day before legalization, then fell toward the high-teens through late 2019. (InvestorPlace)
• US vaping outbreak (EVALI): 2,807 hospitalizations and 68 deaths through February 18, 2020, strongly linked to vitamin E acetate, mostly in THC-containing products. (CDC, archived)

Note: the $300 figure for Tilray is an intraday high, not a closing price. The stock closed that session at $214.

Aftermath

The legalization date marked the top, not a new leg up. With Canadian retail rollout lagging and growers having built more capacity than the legal market could absorb, wholesale prices fell and losses widened across the group through 2019. Tilray closed at $19.93 on November 15, 2019, down more than 70 percent for the year, having traded above $100 in January, according to CMC Markets. Canopy Growth and Aurora Cannabis posted large quarterly losses over the same period as average selling prices slid.

A US health scare deepened the slump. Through the second half of 2019, the Centers for Disease Control and Prevention tracked an outbreak of e-cigarette or vaping product use associated lung injury, known as EVALI. The CDC's final tally counted 2,807 hospitalizations and 68 deaths through February 18, 2020, and identified vitamin E acetate, an additive found mostly in informal-market THC vape cartridges, as strongly linked to the outbreak. The publicity hurt demand for legal vape products and added another weight on cannabis shares during their decline.

The damage stretched into the following years. Aurora Cannabis later carried out a 1-for-12 reverse stock split, executed around May 11, 2020, to keep its share price above the $1 minimum required to stay listed on the New York Stock Exchange. Many smaller producers raised capital repeatedly, diluting holders, while others were acquired or wound down. The marquee names never returned to their 2018 highs.

The corporate strategic bets had mixed outcomes. Constellation Brands kept its large Canopy stake but wrote down its value as Canopy's shares fell, and the promised wave of profitable, branded cannabis products took far longer to arrive than the 2018 optimism implied. No criminal charges defined this episode; it was a valuation collapse, not a fraud, and the losses fell on shareholders who bought the theme near the top.

Lessons for Investors

1. A real catalyst is not a valuation. National legalization was a genuine, scheduled event, and it still did not justify the prices paid. The cannabis stock bubble shows that you can be right about the trend (legal cannabis was coming) and still lose badly because the price already embedded a far larger and more profitable market than materialized. Separate the question "is this happening?" from "what is it worth?"

2. Watch the float, not just the story. Tilray's tiny public float helped drive its move to an intraday $300 and the five halts on a single day. A small number of tradable shares can produce extreme spikes that have little to do with the business and everything to do with mechanics. When a chart goes vertical on light available supply, you are looking at positioning, not fundamentals.

3. A big strategic investor is not a buy signal for you. Constellation's $4 billion USD bet on Canopy was a long-horizon wager on optionality, made on negotiated terms, not an endorsement of the open-market stock price. Treating a corporate deal as proof that retail shares are cheap confuses two very different transactions. The strategic buyer can be right about the decade and you can still overpay today.

4. Capacity built for a forecast is a risk, not a moat. Producers built greenhouses for a demand surge that the slow retail rollout could not feed, and the resulting oversupply gutted selling prices. When an entire industry expands ahead of proven demand, the likely outcome is a glut and falling margins. Be skeptical of valuations that assume supply and demand arrive on schedule and in balance.

5. New, lightly profitable sectors carry headline risk you cannot model. The 2019 vaping illness outbreak, ultimately tied to informal-market additives rather than the legal producers, still dragged on legal cannabis demand and shares. Young industries are exposed to regulatory shifts and public-health shocks that can hit sentiment regardless of any single company's conduct. Size positions in unproven themes so that a surprise headline does not ruin you.

Frequently Asked Questions

What was the cannabis stock bubble in simple terms? The cannabis stock bubble was a speculative run-up in marijuana company shares around Canada's October 17, 2018 legalization of recreational cannabis. Prices soared, Tilray briefly hit an intraday $300 in September 2018, and the sector then lost most of its value through 2019.

Why did the cannabis stock bubble happen? A real catalyst, Canada legalizing recreational cannabis nationally, was paired with thin share floats and a marquee $4 billion investment by Constellation Brands, which made the theme look validated. With most growers unprofitable, prices were set by sentiment, and the buying ran far past what the businesses could support.

How much money was lost in the cannabis stock bubble? Losses were spread across the sector rather than tied to one number. Tilray fell from above $100 in January 2019 to $19.93 by November 15, 2019, down more than 70 percent for the year, and the MJ marijuana ETF dropped from roughly $44 in October 2018 toward the high teens by late 2019.

Could the cannabis stock bubble happen again today? Yes, in form if not in detail. Thematic manias around legalization, technology, or policy change recur whenever a credible story meets cheap money and thin float, and the cannabis sector itself has had later boomlets tied to US legalization headlines.

What is the main lesson from the cannabis stock bubble? Being right about a trend does not protect you from overpaying for it. The most transferable takeaway is to value the business in front of you, on its cash flows and realistic market share, rather than buying a story priced for perfection.

Sources

1. Tilray, Inc. Form 8-K, Q2 2018 Results (IPO terms: shares, price, net proceeds). U.S. Securities and Exchange Commission, EDGAR. https://www.sec.gov/Archives/edgar/data/0001731348/000119312518260597/d613818dex991.htm
2. Constellation Brands, Inc. Form 8-K, Exhibit 99.1: Constellation's $5 Billion CAD ($4 Billion USD) Investment in Canopy Growth Closes. U.S. Securities and Exchange Commission, EDGAR. https://www.sec.gov/Archives/edgar/data/0000016918/000001691818000087/stzex_99-1.htm
3. Canada Gazette, Part II, Vol. 152, No. 14. Order Fixing October 17, 2018 as the Day on which the Cannabis Act Comes into Force (SI/TR/2018-52). https://gazette.gc.ca/rp-pr/p2/2018/2018-07-11/html/si-tr52-eng.html
4. Government of Canada, Department of Justice. Cannabis Legalization and Regulation. https://www.justice.gc.ca/eng/cj-jp/cannabis/
5. U.S. Centers for Disease Control and Prevention (archived). Outbreak of Lung Injury Associated with the Use of E-cigarette, or Vaping, Products (EVALI final update). https://archive.cdc.gov/www_cdc_gov/tobacco/basic_information/e-cigarettes/severe-lung-disease.html
6. CBC News. Nasdaq halts trading in Tilray after pot stock doubles in 2 days. https://www.cbc.ca/news/business/tilray-trade-halt-1.4830282
7. CNBC. Canadian marijuana producer Tilray ends the day up 38% in wild day of trading. https://www.cnbc.com/2018/09/19/marijuana-producer-tilray-up-another-40percent-as-cannabis-stocks-blossom.html
8. The Motley Fool. Tilray Is Partying Like It's 1999 (and It Won't End Well). https://www.fool.com/investing/2018/09/19/tilray-is-partying-like-its-1999-and-it-wont-end-w.aspx
9. CMC Markets / Opto. Canopy Growth, Aurora, Tilray: Will poor earnings keep cannabis stocks down? https://www.cmcmarkets.com/en-gb/opto/canopy-growth-aurora-tilray-will-poor-earnings-keep-cannabis-stocks-down
10. InvestorPlace. Is the MJ ETF Worth a Look as Marijuana Stocks Rise and Fall? https://investorplace.com/2019/03/is-the-mj-etf-worth-a-look-as-marijuana-stocks-rise-and-fall/

Disclaimer

This article is educational content only and is not financial advice. Nothing here is a recommendation to buy, sell, or hold any security. Consult a licensed advisor before making investment decisions.